Advanced Oncotherapy (AVO) – Non-Exec Professor Chris Nutting buys 202,500 shares at 24.67p

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that on Monday 8th and Tuesday 9th May 2017, Professor Chris Nutting, Non-Executive Director of the Company, purchased a total of 202,500 ordinary shares of 25 pence in the Company at an average price of 24.67 pence per Ordinary Share. […]